Articles & Video
Delivery Systems and Strategies for Oligonucleotide Therapeutics
We explore key challenges and solutions in oligo-based drug delivery found in leading programs in the industry.
Report: Oligonucleotide, Peptide, mRNA and Genome Edited Therapeutics State of the Industry 2021
How has the oligonucleotide, peptide, mRNA and genome editing sector transformed over the last year? This industry report provides insight.
Targeted Delivery of Oligonucleotides: Tissue-specific Challenges and Novel Conjugation
Industry experts discussed the latest challenges and learnings in targeted delivery of oligonucleotides.
Rapid characterization of oligonucleotides using microfluidic capillary electrophoresis
Learn how oligo analysis via microfluidic CE-MS avoids using ion pairing agents, which can contaminate mass spectrometers.
Chemical Modification of LNA-based Antisense Oligonucleotides
We explore examples of chemical modification of LNAs for the purpose of optimizing antisense oligonucleotides.
Oligonucleotide scale-up and the impact of equipment with Asahi Kasei Bioprocess America
How much can equipment impact oligonucleotide manufacturing and scale-up? We put the question to Liam Takahashi, Product Engineer at Asahi Kasei Bioprocess America.
Sustainability in peptide and oligonucleotide manufacturing: An interview with Aspen API
eBook: Commercial-scale Production of mRNA and Oligonucleotides
We look at strategies for rapid deployment of mRNA manufacturing, oligonucleotide synthesis, navigating regulatory guidance and scaling up.
Mobile Phase Optimization for the Analysis of Synthetic Oligonucleotides by Ion-Pair Reversed Phase Liquid Chromatography
Analytical Strategies for Oligonucleotide and Peptide Therapeutics - TIDES eBook Series
This TIDES eBook focuses on the challenges, strategies and technologies for measuring quality of oligonucleotides and peptides in therapeutic development.
Challenge to Peptide Manufacturing Technologies
We introduce the benefits of (i) Microwave synthesis and (ii) STag synthesis (tag-assisted LPPS) with some summary data, and discuss our manufacturing strategy depending on the production scale and the stages of development.
Life Sciences Survey: COVID-19 Impacts One Year On
Take part in our industry survey on the impacts of COVID-19 on the life sciences one year on to get exclusive early access to the final report.
45% of companies in oligonucleotide, peptide and mRNA therapeutics increased collaboration during the pandemic
We examine the effects on collaboration in the peptide, oligonucleotide and mRNA therapeutics industry as a result of the COVID-19 pandemic.
Keep up to date with content on Peptide & Oligonucleotide Therapeutics
Keep up to speed every month with top content on peptide, oligonucleotide and mRNA therapeutics.
Personalized Medicine: Neoantigen Cancer Vaccines and T Cell Therapy
We look at precision antigen selection carried out with a personalized immune response profiling platform, demonstrated at TIDES: Oligonucleotide and Peptide Therapeutics.
Delivery is still biggest area of need in peptide, oligonucleotide and mRNA therapeutics
We examine recent trends in technology needs and macromolecular delivery for oligonucleotide, peptide, mRNA and genome edited therapeutics.
A look back at TIDES Asia Virtual Scientific Forum 2021
We explore the best of on-demand webinars from this year's TIDES Asia Virtual Scientific Forum.
eBook: Personalized Peptide Vaccines & Therapies
This ebook focuses on the latest challenges and approaches in producing personalized therapies and vaccines to fight cancer and rare diseases.
Scaling up manufacturing when it’s needed most
Learn how Thermo Fisher Scientific scaled up raw material manufacturing for mRNA production, leaning on decades of experience.